Bank of the Ozarks reduced its position in Amgen, Inc. (NASDAQ:AMGN) by 1.9% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 18,724 shares of the medical research company’s stock after selling 370 shares during the quarter. Amgen comprises about 1.4% of Bank of the Ozarks’ holdings, making the stock its 9th largest position. Bank of the Ozarks’ holdings in Amgen were worth $3,491,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in AMGN. Columbia Asset Management increased its stake in Amgen by 10.4% in the 1st quarter. Columbia Asset Management now owns 23,700 shares of the medical research company’s stock valued at $3,888,000 after buying an additional 2,238 shares during the period. Eliot Finkel Investment Counsel LLC grew its stake in shares of Amgen by 6.2% during the 1st quarter. Eliot Finkel Investment Counsel LLC now owns 32,305 shares of the medical research company’s stock worth $5,300,000 after purchasing an additional 1,880 shares during the period. SRS Capital Advisors Inc. grew its stake in shares of Amgen by 22.9% during the 1st quarter. SRS Capital Advisors Inc. now owns 1,696 shares of the medical research company’s stock worth $278,000 after purchasing an additional 316 shares during the period. Verity Asset Management Inc. acquired a new position in shares of Amgen during the 1st quarter worth $318,000. Finally, Perceptive Advisors LLC acquired a new position in shares of Amgen during the 1st quarter worth $3,281,000. 78.46% of the stock is currently owned by institutional investors.
A number of equities analysts have recently weighed in on the stock. Royal Bank of Canada assumed coverage on shares of Amgen in a research note on Thursday, September 14th. They set a “sector perform” rating and a $192.00 price target on the stock. Bank of America upped their price target on shares of Amgen to $210.00 and gave the stock a “buy” rating in a research note on Thursday, October 5th. Oppenheimer reaffirmed a “buy” rating and set a $203.00 price target on shares of Amgen in a research note on Friday, October 6th. Mizuho reaffirmed a “buy” rating and set a $198.00 price target on shares of Amgen in a research note on Friday, October 6th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $196.00 price target (up from $189.00) on shares of Amgen in a research note on Friday, October 6th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $190.15.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, topping the consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The business had revenue of $5.77 billion for the quarter, compared to analyst estimates of $5.75 billion. During the same period in the previous year, the firm earned $3.02 EPS. The business’s revenue for the quarter was down .7% compared to the same quarter last year. analysts anticipate that Amgen, Inc. will post 12.71 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be given a $1.32 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 annualized dividend and a dividend yield of 2.92%. Amgen’s payout ratio is currently 41.55%.
Amgen declared that its board has initiated a share buyback plan on Wednesday, October 25th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s management believes its shares are undervalued.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of the company’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. Insiders sold a total of 8,575 shares of company stock worth $1,509,339 over the last quarter. Insiders own 0.19% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Bank of the Ozarks Has $3.49 Million Holdings in Amgen, Inc. (AMGN)” was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2018/01/06/bank-of-the-ozarks-has-3-49-million-holdings-in-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.